ZUNVEYL
ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. The medication is used to address cognitive impairment linked to the degeneration of acetylcholine-producing neurons in the brain. While it is intended to manage symptoms, there is no evidence that the drug alters the course of the underlying dementing process. Its therapeutic role is centered on enhancing cholinergic function in patients with this specific form of dementia.
How ZUNVEYL Works
ZUNVEYL acts as a prodrug of galantamine, which is a competitive and reversible inhibitor of the enzyme acetylcholinesterase. It works by increasing the concentration of acetylcholine in the brain by preventing its breakdown, or hydrolysis, by cholinesterase. This process enhances cholinergic function, which is often diminished in Alzheimer's disease due to the degeneration of specific neurons. The drug's impact may diminish over time as the disease advances and fewer cholinergic neurons remain functionally intact.
Details
- Status
- Prescription
- First Approved
- 2024-07-26
- Routes
- ORAL
- Dosage Forms
- TABLET, DELAYED RELEASE
ZUNVEYL Approval History
What ZUNVEYL Treats
2 indicationsZUNVEYL is approved for 2 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Alzheimer's Disease
- Dementia
Drugs Similar to ZUNVEYL
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ZUNVEYL FDA Label Details
ProIndications & Usage
FDA Label (PDF)ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults
ZUNVEYL Patents & Exclusivity
Patents (27 active)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.